One of the main aims of the study was to characterise the profile of the onset of action of moxifloxacin with regard to clinical improvement and cure, in the light of evidence from clinical trials ...

Moxifloxacin (as HCl) 400mg/250mL; soln for IV infusion; latex- and preservative-free. Moxifloxacin inhibits topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial ...

Proportion of patients exhibiting pathological auscultation during treatment with moxifloxacin. Time to onset of antibacterial action: proportion of patients with improvement and cure over time.